Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

G Caleb Alexander^{1

2}, Scott Emerson³, Aaron S Kesselheim⁴

Affiliations

¹ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Department of Biostatistics, University of Washington, Seattle.
⁴ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

G Caleb Alexander et al. JAMA. 2021.

. 2021 May 4;325(17):1717-1718.

doi: 10.1001/jama.2021.3854.

G Caleb Alexander^{1

2}, Scott Emerson³, Aaron S Kesselheim⁴

¹ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Department of Biostatistics, University of Washington, Seattle.
⁴ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

No abstract available

MeSH terms